However, findings from large patient registries involving women exposed to GLP-1 RAs in early pregnancy for the treatment of type 2 diabetes or overweight/obesity are reassuring, suggesting no significant increase in adverse outcomes (79). The gene discussed is GCG; the disease is type 2 diabetes mellitus.